A retrospective clinical analysis of pediatric oncology cases demonstrates that constitutional mismatch repair deficiency can be identified earlier through coordinated pattern recognition across oncology, dermatology, and neuroradiology. Constitutional mismatch repair deficiency, or CMMRD, is a rare autosomal recessive cancer predisposition syndrome caused by biallelic pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2. In individuals carrying these biallelic variants, the condition confers an extraordinarily high risk of early-onset, multi-organ malignancies. Timely diagnosis is frequently delayed because the clinical features show substantial phenotypic overlap with other neurocutaneous disorders, and because atypical tumor presentations hinder the consistent application of established C4CMMRD scoring criteria.
To clarify the mechanisms driving these diagnostic delays, pediatric oncology researchers retrospectively evaluated two representative pediatric case histories. Published in Frontiers in Pediatrics by clinicians affiliated with Italian institutions including Fondazione IRCCS San Gerardo dei Tintori and Fondazione IRCCS Istituto Nazionale dei Tumori, the study examined how diagnostic anchoring and post-transplant complications obstruct timely genetic confirmation. In both patients, identifiable red flags were present across multiple organ systems long before molecular confirmation of constitutional mismatch repair deficiency occurred.
The first case illustrated how prolonged diagnostic anchoring to an alternative disorder impedes accurate recognition. In Case 1, a homozygous pathogenic variant in MSH6 was molecularly confirmed four years after hematopoietic stem cell transplantation for relapsed T-cell lymphoblastic lymphoma. For years prior to that genetic confirmation, the clinical diagnosis had remained anchored to Tuberous Sclerosis Complex. This diagnostic anchoring persisted despite characteristic pigmentary skin abnormalities and negative genetic testing for variants in both the TSC1 and TSC2 genes, showing how adherence to an initial diagnosis can delay the recognition of constitutional mismatch repair deficiency.
The second case highlighted the challenges posed by metachronous tumor presentations and post-transplant testing limitations. Over approximately sixteen years, the patient in Case 2 developed three distinct metachronous malignancies: Burkitt lymphoma, osteosarcoma, and rectal adenocarcinoma.
Across both cases, researchers identified a consistent constellation of multisystem red flags present from an early stage. These clinical indicators spanned oncologic, dermatologic, and neurologic manifestations. In oncology, patients presented with early-onset, multiple, or atypical malignancies. In dermatology, examinations revealed café-au-lait macules and other pigmentary alterations. In neuroradiology, brain imaging detected developmental venous anomalies. Considered together, these findings formed an identifiable cross-specialty clinical pattern that points toward constitutional mismatch repair deficiency rather than isolated pediatric malignancies or other neurocutaneous syndromes.
The investigators retrospectively evaluated both cases using the original C4CMMRD criteria and the revised ERN GENTURIS scoring system. When applied at initial cancer presentation, Case 1 met the clinical testing threshold under both original C4CMMRD criteria and revised ERN GENTURIS guidelines. In contrast, the systems diverged for Case 2. Under original C4CMMRD criteria, Case 2 scored three points and reached the testing threshold at the first cancer diagnosis. Under revised ERN GENTURIS criteria, Case 2 received only two points, reaching the required threshold only after developing a subsequent malignancy.
This scoring discrepancy revealed a crucial weighting nuance regarding pediatric hematologic malignancies under current guidelines. Under revised ERN GENTURIS criteria, T-cell lymphoblastic lymphoma is allocated two points due to its recognized link to constitutional mismatch repair deficiency, whereas atypical Burkitt lymphoma receives less diagnostic weight. The authors observed that assigning atypical Burkitt lymphoma two points, matching the weight granted to T-lymphoblastic lymphoma, would have allowed Case 2 to reach the testing threshold at initial cancer diagnosis under GENTURIS, preventing extensive diagnostic delays.
To prevent diagnostic delays, the authors proposed a pattern-based diagnostic flowchart integrating oncology, dermatology, and neuroradiology. Connecting early-onset or atypical malignancies with pigmentary alterations and developmental venous anomalies facilitates earlier application of scoring criteria across these three domains. The researchers concluded that early, cross-specialty pattern recognition may substantially shorten diagnostic intervals in constitutional mismatch repair deficiency, directly benefiting cancer surveillance protocols and family risk assessment.
Subject of Research: Early clinical diagnosis of constitutional mismatch repair deficiency in pediatric oncology
Article Title: Case Report: From syndromic suspicion to pattern recognition: improving early diagnosis of constitutional mismatch repair deficiency in pediatric oncology
Article References: Romani, F., Schiavello, E., Bettini, L. R., Vendemini, F., Chiaravalli, S., Ricci, M. T., Balduzzi, A. C., Massimino, M., & Cazzaniga, G. (2026). Case Report: From syndromic suspicion to pattern recognition: improving early diagnosis of constitutional mismatch repair deficiency in pediatric oncology. Frontiers in Pediatrics, 14, Article 2014461. https://doi.org/10.3389/fped.2026.2014461
Image Credits: AI Generated
DOI: 10.3389/fped.2026.2014461
Keywords: Constitutional Mismatch Repair Deficiency, CMMRD, Pediatric Oncology, C4CMMRD, ERN GENTURIS, MSH6, PMS2, MLH1, MSH2, Burkitt Lymphoma, T-cell Lymphoblastic Lymphoma, Osteosarcoma, Rectal Adenocarcinoma, Café-au-Lait Macules, Developmental Venous Anomalies, Cancer Predisposition Syndrome, Diagnostic Delay, Hematopoietic Stem Cell Transplantation
News Source: Nathaniel Bowman. (November 18, 2026). Pediatric Cancer Cases Highlight Pattern Recognition to Accelerate CMMRD Diagnosis. Scienmag.



